Penumbra Inc (PEN) Q1 2017 10-Q Quarterly Earnings

Short answer

Penumbra Inc (PEN) filed its Q1 2017 10-Q quarterly report on May 9, 2017 for the quarter ended Mar 31, 2017.

AI summary of MD&A and risk factor updates

Revenue $73.2M, up 26.4% YoY from $57.9M
Operating margin (2.8%) vs 3.2% YoY, gross margin 65.2% vs 68.9%
Best segment Peripheral Vascular: $23.0M, up 38.0%; Neuro: $50.2M, up 21.7%
Cash $109.4M vs $13.2M, operating cash flow $2.2M vs $(2.1)M
Equity offering generated $106.3M net proceeds; expected R&D, clinical trials, acquisitions and working capital uses

No material changes to risk factors since the December 31, 2016 10-K
Product liability exposure: Montgomery litigation alleges Penumbra Coil 400 injuries and potential $35 million damages
Regulatory risk: delayed or unsuccessful regulatory approvals could cause quarterly revenue variability
Competitive risk: larger, well-capitalized competitors threaten market share and physician adoption
Foreign exchange risk: 33.8% of quarterly revenue came internationally, primarily in euros and Japanese yen

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.